Thermo Fisher Scientific (California, USA) has signed an agreement with GE Healthcare (St Giles, UK) to sell business assets for $1.06 billion. Thermo Fisher committed to sell its cell culture, gene modulation, and magnetic beads businesses in 2013 to expedite approval of its pending acquisition of Life Technologies by the European Commission.
Thermo Fisher Scientific (California, USA) has signed an agreement with GE Healthcare (St Giles, UK) to sell business assets for $1.06 billion. Thermo Fisher committed to sell its cell culture, gene modulation, and magnetic beads businesses in 2013 to expedite approval of its pending acquisition of Life Technologies by the European Commission.
The combined revenue of the three businesses, which form part of Thermo Fisher’s Analytical Technologies Segment, is estimated to be $250 million in 2013. Kieran Murphy, president and CEO of GE Healthcare’s Life Sciences division, said: “In addition to providing us with new approaches to drug discovery and biomedical research, this acquisition is a significant step forward for our customers in biopharmaceutical manufacturing.” He added: “By expanding our production facilities to three continents, we will be able to offer the biopharmaceutical industry greater confidence in the security of supply of cell culture media and sera, a key part of their production process.”
For further information visit www.gehealthcare.com
Traditional Chinese Medicine’s Effects on Liver Cancer Measured Using New UHPLC–QTOF-MS System
April 22nd 2024Scientists from Anhui University of Chinese Medicine in Hefei, China recently investigated the mechanisms behind what makes huachansu tablets, a type of traditional Chinese medicine (TCM), effective against liver cancer.